Bioptik Technology (4161) - Net Assets
Based on the latest financial reports, Bioptik Technology (4161) has net assets worth NT$974.69 Million TWD (≈ $30.71 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.57 Billion ≈ $49.52 Million USD) and total liabilities (NT$597.14 Million ≈ $18.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Bioptik Technology to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$974.69 Million |
| % of Total Assets | 62.01% |
| Annual Growth Rate | 1.18% |
| 5-Year Change | 40.34% |
| 10-Year Change | N/A |
| Growth Volatility | 8.06 |
Bioptik Technology - Net Assets Trend (2017–2025)
This chart illustrates how Bioptik Technology's net assets have evolved over time, based on quarterly financial data. Also explore 4161 current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Bioptik Technology (2017–2025)
The table below shows the annual net assets of Bioptik Technology from 2017 to 2025. For live valuation and market cap data, see 4161 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$974.69 Million ≈ $30.71 Million |
+7.67% |
| 2024-12-31 | NT$905.27 Million ≈ $28.52 Million |
+9.84% |
| 2023-12-31 | NT$824.15 Million ≈ $25.97 Million |
+14.81% |
| 2022-12-31 | NT$717.83 Million ≈ $22.62 Million |
+3.35% |
| 2021-12-31 | NT$694.54 Million ≈ $21.88 Million |
-5.59% |
| 2020-12-31 | NT$735.66 Million ≈ $23.18 Million |
-4.26% |
| 2019-12-31 | NT$768.38 Million ≈ $24.21 Million |
-5.34% |
| 2018-12-31 | NT$811.73 Million ≈ $25.57 Million |
-8.53% |
| 2017-12-31 | NT$887.42 Million ≈ $27.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bioptik Technology's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$75.63 Million | 7.80% |
| Other Components | NT$893.73 Million | 92.20% |
| Total Equity | NT$969.36 Million | 100.00% |
Bioptik Technology Competitors by Market Cap
The table below lists competitors of Bioptik Technology ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Q32 Bio Inc
NASDAQ:QTTB
|
$44.30 Million |
|
Shivalik Rasayan Limited
NSE:SHIVALIK
|
$44.30 Million |
|
Genetec Technology Bhd
KLSE:0104
|
$44.34 Million |
|
Laurion Mineral Exploration Inc
V:LME
|
$44.36 Million |
|
Dongwoo Farm To Table Co.Ltd
KQ:088910
|
$44.28 Million |
|
Century Lithium Corp.
V:LCE
|
$44.24 Million |
|
Major Cineplex Lifestyle Leasehold Property Fund
BK:MJLF
|
$44.23 Million |
|
Marygold Companies Inc
NYSE MKT:MGLD
|
$44.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioptik Technology's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 901,270,000 to 969,360,000, a change of 68,090,000 (7.6%).
- Net income of 71,192,000 contributed positively to equity growth.
- Dividend payments of 15,882,000 reduced retained earnings.
- Other factors increased equity by 12,780,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$71.19 Million | +7.34% |
| Dividends Paid | NT$15.88 Million | -1.64% |
| Other Changes | NT$12.78 Million | +1.32% |
| Total Change | NT$- | 7.55% |
Book Value vs Market Value Analysis
This analysis compares Bioptik Technology's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.45x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$17.18 | NT$23.50 | x |
| 2018-12-31 | NT$16.66 | NT$23.50 | x |
| 2019-12-31 | NT$15.80 | NT$23.50 | x |
| 2020-12-31 | NT$14.41 | NT$23.50 | x |
| 2021-12-31 | NT$13.60 | NT$23.50 | x |
| 2022-12-31 | NT$14.04 | NT$23.50 | x |
| 2023-12-31 | NT$15.97 | NT$23.50 | x |
| 2024-12-31 | NT$15.07 | NT$23.50 | x |
| 2025-12-31 | NT$16.21 | NT$23.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioptik Technology utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.34%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.50%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.62x
- Recent ROE (7.34%) is above the historical average (3.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -3.84% | -7.08% | 0.30x | 1.78x | NT$-121.50 Million |
| 2018 | 3.28% | 5.08% | 0.32x | 1.99x | NT$-54.02 Million |
| 2019 | 0.69% | 0.93% | 0.36x | 2.04x | NT$-71.03 Million |
| 2020 | -8.21% | -12.35% | 0.33x | 2.02x | NT$-133.04 Million |
| 2021 | 3.27% | 3.06% | 0.48x | 2.21x | NT$-46.43 Million |
| 2022 | 6.78% | 6.32% | 0.51x | 2.12x | NT$-23.02 Million |
| 2023 | 10.46% | 10.35% | 0.55x | 1.83x | NT$3.78 Million |
| 2024 | 10.38% | 10.81% | 0.58x | 1.65x | NT$3.44 Million |
| 2025 | 7.34% | 8.50% | 0.53x | 1.62x | NT$-25.74 Million |
Industry Comparison
This section compares Bioptik Technology's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,676,225,222
- Average return on equity (ROE) among peers: 7.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioptik Technology (4161) | NT$974.69 Million | -3.84% | 0.61x | $44.28 Million |
| Hi-Clearance (1788) | $1.63 Billion | 15.45% | 0.61x | $190.76 Million |
| Radiant Innovation (3373) | $1.02 Billion | 2.81% | 0.09x | $25.35 Million |
| Wellell Inc (4106) | $1.31 Billion | 13.81% | 0.24x | $70.90 Million |
| Rossmax International Ltd (4121) | $1.34 Billion | 1.24% | 0.71x | $38.32 Million |
| United Orthopedic (4129) | $2.93 Billion | 3.48% | 0.91x | $298.97 Million |
| Dynamic Medical Technologies (4138) | $1.47 Billion | 7.66% | 0.52x | $70.45 Million |
| Ok Biotech Co Ltd (4155) | $2.40 Billion | 0.12% | 0.28x | $59.00 Million |
| AViTA Corporation (4735) | $888.28 Million | 4.81% | 0.39x | $36.39 Million |
| TAIDOC TECHNOLOGY CORP (4736) | $2.11 Billion | 16.22% | 0.51x | $375.60 Million |
About Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. It offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch Glucose Monitoring System for Dogs and Cats. The company also prov… Read more